Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. - Wikidata - awgldk - TriplyDB

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

http://www.wikidata.org/entity/Q39471967

about

Antifungal susceptibility testing: practical aspects and current challenges.In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Population pharmacokinetic model for gatifloxacin in pediatric patients.Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.Exploring the role of the immune response in preventing antibiotic resistance.

P2860

Q33975757-E06629FD-B3A7-4170-AA04-51CD3D7EFD5E Q33979115-3DF1F76D-454B-45E2-94E5-F041AE9F5FCE Q34274190-14FF34A3-BBFA-40AC-A27E-65673E347FA4 Q35758967-7A1711AB-3484-4224-90D1-2C8904696C5D Q36047311-BD377812-EEEB-4FAD-B698-286E6066F424 Q36870838-9B76B5C6-66D4-407A-A187-A2C5169905E1 Q37428654-0F627EB5-7550-4AEC-B92C-3E8A5D079203 Q37733667-C8262A0C-DDAD-471B-B587-3F5DD12FB2F9 Q38718394-F07B0F75-3746-46F4-96E3-E0260E30A2DA Q39895097-1691026B-6EAC-4389-B895-FF236A7EB965 Q39955190-72A009BE-76C7-4668-827F-607DF01B85F1 Q42016758-A05216AC-F855-447E-AAD7-7CEBF8F7B42E Q42040822-8326B573-ED84-4E70-A760-D9048688024A Q44028719-089F2B80-39E5-42CD-8060-8271FAF7A9BA

P2860

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

http://www.wikidata.org/entity/Q39471967

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

@en

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

@nl

type

label

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

@en

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

@nl

prefLabel

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

@en

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

@nl

P1433

Q39471967-D4DEDB54-7C6C-49EB-B8FC-9FEB1547A145

P1476

Q39471967-0760747A-5829-4A5B-8CA2-A8CD5939F8B3

P2093

Q39471967-50EB5210-9E72-4609-9AE6-8F91C92757A7

Q39471967-6A560860-A9AF-4788-A2B3-B0F4C652C0DF

Q39471967-CEB589A3-1E07-41A6-9499-4A2A97CB409B

Q39471967-D92C94E4-DB34-43B7-9540-601CF880F9B3

P2860

Q39471967-0634FBAC-39B3-4329-852F-1B26502E9613

Q39471967-12448FC4-530A-4FE1-9B39-3904296F51F5

Q39471967-28405710-6186-4AAA-8AE0-6A94BF558712

Q39471967-2CECEFCB-1DF4-4DA2-B25A-E795E161A87C

Q39471967-39A47ACE-306B-41A6-B007-4A7088C0B3FB

Q39471967-3A5778A3-FCB9-44EB-B8F5-03775DC2DEF3

Q39471967-45B13905-7713-4918-A178-97CC7DE1CEB0

Q39471967-52F7F907-E111-4CDC-8D4D-687C1C946876

Q39471967-67CE8FD1-EA94-4D9C-89C2-6707B9CCFA38

Q39471967-69C63A8C-7466-4823-8475-86FF804A39ED

P304

Q39471967-91426B8F-74FA-4640-82C3-9D414C5C0A24

P31

Q39471967-1B0D96DF-586F-4FE3-968C-27A8B816E113

P356

Q39471967-593A4099-31E3-4B62-BE71-9CB6150E4DD1

P407

Q39471967-472D1830-0866-47EA-8D5C-73222D8B436F

P433

Q39471967-03D4A152-79DB-4259-847E-7A79198C0234

P478

Q39471967-6E25E94C-CA6E-4B45-AD7D-61DF5F63E3C5

P577

Q39471967-9310F96A-FFA4-4D63-B2C2-8965C9E8698D

P698

Q39471967-4E8B54DB-6985-49FB-9C9D-57B3683CB119

P932

Q39471967-07859F6F-4DD4-4503-8A07-127C75A14328

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo

@en

P2093

D Andes

http://www.w3.org/2001/XMLSchema#string

J W Mouton

http://www.w3.org/2001/XMLSchema#string

M L van Ogtrop

http://www.w3.org/2001/XMLSchema#string

W A Craig

http://www.w3.org/2001/XMLSchema#string

P2860

Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.

Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test

Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

What is synergy?

Synergy, additivism and antagonism in immunosuppression. A critical review.

In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.

The search for synergy: a critical review from a response surface perspective.

Definitions of antibacterial interactions in animal infection models.

P304

2473-2478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.43.10.2473

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

1999-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10508027

http://www.w3.org/2001/XMLSchema#string

P932

89503

http://www.w3.org/2001/XMLSchema#string